Biopharma

Understanding the biopharma industry landscape

Biopharma is a dynamic segment of the life sciences industry focused on therapies derived from biological sources, including proteins, cells and genetic material. The sector encompasses biologics and biosimilars, cell and gene therapies, small molecules, biotechnology, contract research and manufacturing organizations (CROs and CMOs), and digital health innovators.

Across these subsegments, organizations are advancing scientific innovation while navigating research and development intensity, funding constraints, evolving regulatory and data requirements, and increasing manufacturing and supply chain complexity. From preclinical development to commercialization, success requires balancing growth opportunities with development costs, reimbursement and market access pressures, talent shortages, intellectual property considerations and regulatory demands.

At the same time, digital transformation, artificial intelligence-enabled analytics and advanced manufacturing technologies are reshaping how biopharma companies operate, scale and compete.

RSM provides integrated assurance, tax and consulting services tailored to biopharma companies, helping organizations manage risk, adapt to change and build resilient, scalable operating models throughout the lifecycle.

Helping biopharma's scale at the speed of change

Preclinical

Scale your people and infrastructure as you enter your clinical trials.

Clinical

Manage your cash flow as you work through the trial phase.

Precommercial

Formalize a commercial launch plan and team.

Commercial

Effectively manage your gross margin, market access and supply.

Biopharma industry trends

Biopharma organizations are navigating a set of interconnected trends that are redefining commercialization, capital strategy, innovation models and long‑term growth.

Commercialization and market access

Biopharma companies must align launch strategies with reimbursement, payer expectations and provider requirements to accelerate patient access and sustain commercial performance.

Accessing capital markets

Capital access is increasingly diversified, requiring biopharma companies to navigate a broader mix of traditional, alternative and global funding sources to support growth.

Process gear with time indicator linked to users, illustrating workflow efficiency and collaboration.

Human capital evolution

Biopharma organizations are rethinking talent models by combining specialized talent with AI, automation and outsourcing to drive speed, flexibility and innovation.

Business and technology transformation

Digital platforms, analytics and artificial intelligence are reshaping drug discovery and development, enabling faster insights, more targeted therapies and improved patient outcomes.

Licensing and M&A strategy

Licensing and mergers and acquisitions continue to fuel innovation, with emerging companies advancing early-stage science and established players selectively acquiring or licensing later‑stage assets.

Evolving drug development models

Drug development is becoming more flexible and partnership‑driven as companies balance speed, risk, cost and regulatory complexity in a changing global environment.

Government building with balance scale, representing tax regulation, compliance, or financial justice.

Government and regulatory changes

Regulatory, reimbursement and policy shifts are influencing how biopharma companies design trials, secure approvals, price therapies and plan market entry.

Biopharma industry outlook

The biopharma industry outlook remains dynamic, driven by innovation and evolving market, regulatory and operational factors.

Biopharma industry services and solutions

RSM takes a middle market-first approach, delivering a right‑sized, integrated model designed to support biopharma companies at every stage of the lifecycle. With technology enablement as a core strength, we help organizations move with speed and focus, aligning strategy, execution and governance to create practical, scalable solutions.

Our biopharma services are built to deliver value quickly, helping companies manage complexity, pursue growth and adapt as priorities shift.

We provide key tax and assurance services as well as the following consulting services for biopharma companies:

: Guides biopharma companies through commercialization readiness by aligning strategy, finance, operations, compliance and technology for a successful product launch.

Integrated launch planning services

: Helps biopharma organizations manage pricing, contracts and gross‑to‑net processes to improve revenue accuracy, compliance and forecasting.

Revenue contract management services

: Delivers scalable, outsourced finance and accounting services tailored to the operational and regulatory needs of life sciences companies.

RSM Catamaran biopharma managed services

: Supports biopharma companies through mergers, acquisitions and capital events with financial, accounting and transaction advisory services.

Transaction advisory and deal services

: Technology solutions for biopharma companies Provides technology strategy (including Microsoft and NetSuite), implementation and optimization services to help biopharma organizations streamline operations, improve data visibility, enhance decision making and support scalable growth.

: Helps biopharma organizations identify, assess and manage operational, regulatory, cybersecurity and compliance risks throughout the product lifecycle.

Risk management and compliance services

Biopharma industry insights and client stories

Meet our biopharma leadership team

Frequently asked questions (FAQs)

Biopharma leaders often face similar questions as they navigate growth, commercialization and scale. The FAQs below address common issues we see across the biopharma lifecycle.

: As biopharma companies grow, they must balance innovation with regulatory, financial and operational demands—often while preparing for commercialization, funding events or increased investor scrutiny. The challenge is building scalable finance, compliance and technology foundations without overengineering or slowing progress.

: Commercialization readiness goes beyond clinical success. It requires launch-ready infrastructure across finance, data, compliance, supply chain and market access to support pricing, gross-to-net visibility and revenue confidence—before products reach the market.

: As products near commercialization, complex contracts, chargebacks, rebates and payer dynamics make revenue visibility critical. Strong data, systems and controls help biopharma leaders forecast accurately, manage risk and support board‑ and investor‑level decisions.

: Investor‑grade readiness requires credible controls, reporting and governance scaled to a company’s stage. A right‑sized approach—often supported by technology and managed services—helps biopharma companies prepare for capital events while maintaining speed and flexibility.

: Life sciences organizations are using AI to accelerate research, improve opperational efficiencies, optimize commercial performance and automate business processes while strengthening data-driven decision-making.

Contact our biopharma professionals

Subscribe to Life Sciences Insights

Knowledge is power. Stay up to date with key life sciences trends and timely insights, delivered straight to your inbox.

THE POWER OF BEING UNDERSTOOD

ASSURANCE | TAX | CONSULTING

RSM US LLP is a limited liability partnership and the U.S. member firm of RSM International, a global network of independent assurance, tax and consulting firms. The member firms of RSM International collaborate to provide services to global clients, but are separate and distinct legal entities that cannot obligate each other. Each member firm is responsible only for its own acts and omissions, and not those of any other party. Visit rsmus.com/about for more information regarding RSM US LLP and RSM International.

Technology alliance platforms

Featured topics

Real Economy publications

Platform user insights and resources

About us

Experience RSM

Spotlight on culture

Work with us